1. Global Vaccines 202X: Access, Equity, Ethics Novartis Vaccines & Diagnostics Clement Lewin PhD MBA Head Medical Affairs & Policy Region North America Philadelphia; May 5 th, 2011 1 | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

2. Novartis Vaccines & Diagnostics Overview  Leading manufacturer of influenza, pediatric, and meningitis vaccines  Globally produce over 500 million doses of vaccine, 70% to developing countries  Invested over $2 bn in vaccine production since 2006 including large partner with HHS on Pandemic Influenza  Institute for global health (NVGH) launched in 2009 to develop vaccines for neglected diseases 2 | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

3. Major global presence Novartis Vaccines and Diagnostics locations ~5,000 Associates Worldwide* Cambridge Global Leadership Center Paris Diagnostics Siena/Rosia Vaccines manufacturing, R&D Liverpool Vaccines manufacturing Amsterdam Vaccines data management Ankleshwar Vaccines manufacturing Holly Springs Vaccines manufacturing Hong Kong Diagnostics Emeryville Diagnostics headquarters & Vaccines administration Basel Vaccines Singapore Vaccines Hyderabad Development Marburg Vaccines manufacturing Buenos Aires Vaccines 3 | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

4. Focus going forward is on new disease targets and increased global access Established Markets Vaccine Preventable Diseases Expand Access Globally New Disease Targets Developing Countries Develop New Vaccines for Global Unmet Needs Current Vaccine Market Develop New Vaccines for Established Markets 4 | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

5. Expanding sustainable access in emerging markets is critical for a healthy vaccines industry North America 4% (5) Europe 7% (9) LATAM 9% (11) Asia 55% (72) Africa 27% (35) Global Birth Cohort Distribution Estimate of Annual Births, m  Vast majority of births in Asia, Africa, LATAM  Many markets currently addressed through GAVI/UNICEF mechanisms (including AMCs)  Dramatic expansion in local and regional players  Multi-nationals will increasingly focus resources on expanding uptake in these markets in the future 5 | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

6. Challenges will need to be overcome  Harmonizing regulatory pathways for new vaccine technologies and production platforms  Sustainable investment, cost, and pricing models to support access and innovation  Improving public perceptions of value proposition of newer generations of vaccines  Building continued faith in vaccines and their public health impact and benefits at the individual level 6 | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

7. 7